{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:13:50Z","timestamp":1793744030618,"version":"4.6.1"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JAK inhibitors in patients with IMIDs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A systematic search of electronic databases was conducted to identify randomized controlled trials (RCTs) that evaluated the safety of JAK inhibitors in patients with IMIDs including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriasis (PsO), and psoriatic arthritis (PsA). The primary outcome of interest was the incidence of herpes zoster infection. Network meta-analysis was performed to compare the risk of herpes zoster among different JAK inhibitors and placebo.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A network meta-analysis was conducted using data from 47 RCTs including 24,142 patients. In patients with IMIDs, peficitinib 100\u00a0mg QD was associated with the highest risk of herpes zoster infection in patients with IMIDs, followed by baricitinib 4\u00a0mg QD and upadacitinib 30\u00a0mg QD. No difference in herpes zoster risk was found for other JAK inhibitors compared with placebo. Subgroup analysis indicated that higher incidence of herpes zoster was found in patients treated by baricitinib 4\u00a0mg QD, peficitinib 100\u00a0mg QD, and upadacitinib 30\u00a0mg QD only in patients with RA.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our study suggests that some JAK inhibitors, particularly peficitinib, baricitinib, and tofacitinib, are associated with a higher risk of herpes zoster infection in patients with IMIDs.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1241954","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T01:40:53Z","timestamp":1691458853000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":104,"title":["Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Qingling","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe","year":"2017","journal-title":"J. Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatol. Oxf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102902","DOI":"10.1016\/j.autrev.2021.102902","article-title":"JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis","volume":"20","author":"Campanaro","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS one"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: A phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatol. Oxf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","article-title":"Meta-regression of herpes zoster incidence worldwide","volume":"11","author":"Curran","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and No or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"Jama"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","article-title":"Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: A systematic review of clinical trials and real-world studies","volume":"43","author":"Gialouri","year":"2023","journal-title":"Rheumatol. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: Is expectation the root of all headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/1756-185X.14447","article-title":"Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis","volume":"26","author":"Harkins","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"Inthout","year":"2016","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin. Trials"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: Results from a randomised, dose-finding study (Darwin 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16828","article-title":"Risk of herpes zoster according to past history in the general population: The Japanese Shozu herpes zoster study","author":"Kawahira","year":"2023","journal-title":"J. Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","article-title":"Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Z Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e002559","DOI":"10.1136\/rmdopen-2022-002559","article-title":"Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: A phase 3, randomised, double-blind, placebo-controlled study","volume":"9","author":"Leng","year":"2023","journal-title":"RMD Open"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e199735","DOI":"10.1001\/jamanetworkopen.2019.9735","article-title":"Use of prediction intervals in network meta-analysis","volume":"2","author":"Lin","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14309\/01.ajg.0000859584.83560.ef","article-title":"Efficacy and safety of upadactinib induction therapy in patients with moderately to severely active Crohn's disease: Results from a randomized phase 3 U-EXCEL study","volume":"10","author":"Loftus","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"Mcinnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: Past, present and future","volume":"21","author":"Mcinnes","year":"","journal-title":"Nat. Rev. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: Past, present and future","volume":"21","author":"Mcinnes","year":"","journal-title":"Nat. Rev. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/biology11070973","article-title":"Immune-mediated diseases from the point of view of psychoneuroimmunoendocrinology","volume":"11","author":"Ortega","year":"2022","journal-title":"Biol. (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of crohn's disease: Results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"B54","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0025-6196(11)61146-4","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: Application and practice using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol. Health"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1759720X20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: Focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/s1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/antibiotics12040757","article-title":"Pharmacological treatment of herpes zoster and factors associated with its recurrence","volume":"12","author":"Valladales-Restrepo","year":"2023","journal-title":"Antibiot. (Basel)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: A double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"Van Der Heijde","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"Van Der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"Van Der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"Van Der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"Van Oorschot","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"Van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B75","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe crohn's disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.3390\/jcm11154459","article-title":"Efficacy and safety of JAK inhibitors for rheumatoid arthritis: A meta-analysis","volume":"11","author":"Wang","year":"2022","journal-title":"J. Clin. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (Darwin 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2023.2172808","article-title":"JAK inhibitors in rheumatology","author":"Yamaoka","year":"2023","journal-title":"Immunol. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"42","author":"Yang","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in asian patients with moderate to severe chronic plaque psoriasis: A phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J. Dermatol Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1241954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T01:40:56Z","timestamp":1691458856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1241954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":81,"alternative-id":["10.3389\/fphar.2023.1241954"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1241954","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"article-number":"1241954"}}